SEKISUI XenoTech is adding human and minipig to the company’s list of species with dermal subcellular fractions available as standard test systems for the development of safer new products. Subcellular fractions are widely used in drug discovery and preclinical drug development to evaluate the in vitro metabolism of new therapeutics.
Many drug-metabolizing enzymes of the liver and other organs are also expressed in the skin, including cytochrome p450 (CYPs), flavin monooxygenases, esterases/amides, UDP-glucuronosyltransferases, glutathione S-transferases and sulfotransferases. Although specific activities of these cutaneous enzymes are lower, they can be significant enough to generate adverse reactions to xenobiotics delivered to or through the skin, such as creams, gels, sprays or adhesive patches.
Zell Woodworth, Products Division Director for SEKISUI XenoTech, commented, “Our biggest demand so far has come from European countries where animal use in biomedical/cosmetic research is highly restricted and most testing has to be performed in vitro. Generally, customers who are interested in skin subcellular fractions are looking for local substrate loss or metabolite formation in the skin during transdermal/topical delivery of a drug…”
Learn more about:
About the Authors
Subscribe to our Newsletter
Stay up to date with our news, events and research
Do you have a question or a request for upcoming blog content?
We love to get your feedback